← Leaderboards
Mohammad Athar
Columbia University Health Sciences
$24,147,707
Attributed
$25,238,061
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,278,952 · 15
By mechanism
U54$26,734,221 · 4
U01$7,697,017 · 2
R01$4,856,946 · 3
UG3$2,180,708 · 1
P01$1,439,701 · 2
R21$1,206,859 · 2
Top collaborators
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- David Rinsey Bickers$13,811,205
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesToxic EffectResponseSkinExposure ToMolecularPathogenesisBaseMediatingArsenicalsCutaneousSignal TransductionProgramsPathway InteractionsAnimalsAntidotesMolecular TargetSkin LesionProteinsMouse ModelLewisiteBullaInflammationRegulation
Grant awards (65)
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$521,500
UG3 · FY2025 · AR
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$824,145
UG3 · FY2024 · AR
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$630,176
U01 · FY2024 · AR · contact PI
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$147,015
U01 · FY2024 · AR · contact PI
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$835,063
UG3 · FY2023 · AR
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$737,659
U01 · FY2023 · AR · contact PI
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$145,530
U01 · FY2023 · AR · contact PI
UAB Research Center of Excellence in Arsenicals$3,760,317
U54 · FY2022 · ES · contact PI
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$739,531
U01 · FY2022 · AR · contact PI
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury$732,152
U54 · FY2022 · ES · contact PI
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)$585,746
U54 · FY2022 · ES · contact PI
Administrative Core$219,646
U54 · FY2022 · ES · contact PI
UAB Research Center of Excellence in Arsenicals$3,760,306
U54 · FY2021 · ES · contact PI
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$740,941
U01 · FY2021 · AR · contact PI
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury$719,082
U54 · FY2021 · ES · contact PI
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)$575,245
U54 · FY2021 · ES · contact PI
Administrative Core$365,725
U54 · FY2021 · ES · contact PI
Core 3: Rexinoid Screening and Animal Core$186,229
P01 · FY2021 · CA · contact PI
Core 3: Rexinoid Screening and Animal Core$59,920
P01 · FY2021 · CA · contact PI
UAB Research Center of Excellence in Arsenicals$3,760,067
U54 · FY2020 · ES · contact PI
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury$741,015
U01 · FY2020 · AR · contact PI
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury$712,438
U54 · FY2020 · ES · contact PI
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)$569,977
U54 · FY2020 · ES · contact PI
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed mice$330,750
R01 · FY2020 · ES · contact PI
Core 3: Rexinoid Screening and Animal Core$297,974
P01 · FY2020 · CA · contact PI
Administrative Core$213,731
U54 · FY2020 · ES · contact PI
15th Annual NIH CounterACT Network Research Symposium$150,000
U54 · FY2020 · ES · contact PI
UAB Research Center of Excellence in Arsenicals$3,760,191
U54 · FY2019 · ES · contact PI
Blocking Arsenicals-induced Cutaneous Injury$733,530
U01 · FY2019 · NS · contact PI
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury$705,969
U54 · FY2019 · ES · contact PI
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)$564,801
U54 · FY2019 · ES · contact PI
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed mice$330,750
R01 · FY2019 · ES · contact PI
Core 3: Rexinoid Screening and Animal Core$293,606
P01 · FY2019 · CA · contact PI
Administrative Core$211,790
U54 · FY2019 · ES · contact PI
UAB Research Center of Excellence in Arsenicals$3,850,010
U54 · FY2018 · ES · contact PI
Blocking Arsenicals-induced Cutaneous Injury$733,530
U01 · FY2018 · NS · contact PI
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury$722,383
U54 · FY2018 · ES · contact PI
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)$577,930
U54 · FY2018 · ES · contact PI
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed mice$330,750
R01 · FY2018 · ES · contact PI
Core 3: Rexinoid Screening and Animal Core$300,986
P01 · FY2018 · CA · contact PI
Administrative Core$216,715
U54 · FY2018 · ES · contact PI
Blocking Arsenicals-induced Cutaneous Injury$733,530
U01 · FY2017 · NS · contact PI
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed mice$330,750
R01 · FY2017 · ES · contact PI
Core 3: Rexinoid Screening and Animal Core$300,986
P01 · FY2017 · CA · contact PI
Blocking Arsenicals-induced Cutaneous Injury$147,500
U01 · FY2017 · NS · contact PI
Blocking Arsenicals-induced Cutaneous Injury$733,530
U01 · FY2016 · NS · contact PI
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed mice$330,750
R01 · FY2016 · ES · contact PI
Blocking Arsenicals-induced Cutaneous Injury$733,530
U01 · FY2015 · NS · contact PI
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer$303,988
R01 · FY2015 · CA · contact PI
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer$294,868
R01 · FY2014 · CA · contact PI
Therapeutic Intervention of Lewisite-Mediated Cutaneous Blistering-Inflammation$73,500
R21 · FY2014 · AR · contact PI
Therapeutic Intervention of Lewisite-Mediated Cutaneous Blistering-Inflammation$366,251
R21 · FY2013 · AR · contact PI
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer$285,749
R01 · FY2013 · CA · contact PI
Therapeutic Intervention of Lewisite-Mediated Cutaneous Blistering-Inflammation$366,251
R21 · FY2012 · AR · contact PI
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer$303,988
R01 · FY2012 · CA · contact PI
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer$303,988
R01 · FY2011 · CA · contact PI
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention$334,113
R01 · FY2010 · ES · contact PI
Developing a murine model for arsenic-induced skin neoplasm$181,294
R21 · FY2010 · ES · contact PI
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention$337,488
R01 · FY2009 · ES · contact PI
Developing a murine model for arsenic-induced skin neoplasm$219,563
R21 · FY2009 · ES · contact PI
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention$319,725
R01 · FY2008 · ES · contact PI
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention$316,789
R01 · FY2007 · ES · contact PI
Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention$402,500
R01 · FY2006 · ES · contact PI
Chemo-prevention of UVB-induced Basal Cell Carcinomas+/*$81,750
R03 · FY2004 · CA
Chemo-prevention of UVB-induced Basal Cell Carcinomas$81,750
R03 · FY2003 · CA